… This study revealed little or no benefit of serum therapy. A total of 41 patients were treated,
of whom 5 received Maragliano’s original serum. Treatment lasted from 3 days to 7 months …

… reactivation of Mycobacterium tuberculosis infection in SCID mice and found that passive
immunization with sera obtained from mice treated with detoxified M. tuberculosis extracts (…

… ready application as an adjunct to therapy of human tuberculosis. Mycobacterium tuberculosis
remains one of the most … Effect of IVIg or human serum albumin or maltose on growth of M. …

… Because the serum IL-12p40, IL-10, TNF-α, and … Mycobacterium tuberculosis (M tuberculosis).
These parameters could be used in follow-up as indicators of the success of APTB therapy…

… Active pulmonary tuberculosis (APTB) is associated with a failure of the host … Mycobacterium
tuberculosis (Mtb). The objective of this study was to quantify and assess the role of serum …

… Mycobacterium tuberculosis (Mtb) is a major cause of morbidity and mortality worldwide. Slow
progress has been made in lessening the impact of tuberculosis … of adjunctive therapy that …

… -fast bacteria are produced in the serum of patients with pulmonary tuberculosis, and that the
… with active pulmonary tuberculosis before antituberculosis chemotherapy. Nonrespiratory: …

… Increasing evidence suggests that mycobacteria change the … of utilizing miRNA-based
therapy itself or canonically with a … shown potential as a new therapeutic intervention. However, …

… therapeutic immunization could impact the course of Mycobacterium tuberculosis infection
with use of a candidate … We identified potent T cell antigens of Mycobacterium tuberculosis (M. …

… for latent Mycobacterium tuberculosis infection and risk of progression to tuberculosis (TB)
disease are needed to better identify individuals to target for preventive therapy, predict …